Rituximab in membranous nephropathy after haematopoietic stem cell transplantation.
Ferrannini
Michele
M
Vischini
Gisella
G
Di Daniele
Nicola
N
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007166:Immunosuppressive Agents; D000069283:Rituximab